The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.

摘要: The presence of an aberrantly activated epidermal growth factor receptor (EGFR) in many epithelial tumors, due to its overexpression, activating mutations, gene amplification and/or overexpression ligands, represent the fundamental basis underlying use EGFR tyrosine kinase inhibitors (EGFR-TKIs). Drugs inhibiting have different mechanisms action; while erlotinib and gefitinib inhibit intracellular kinase, monoclonal antibodies like cetuximab panitumumab bind extracellular domain both immunomediated anti-cancer effect function. On other hand, interleukin-8 has tumor promoting as well neo-angiogenesis enhancing effects several attempts been made activity. One these is based on old sulfone antibiotic dapsone that demonstrated system actions. Erlotinib typically gives a rash recently proven come out via up-regulated keratinocyte synthesis with histological features reminiscent typical neutrophilic dermatoses. In this review, we report experimental evidence shows improve quality life erlotinib-treated patients by ameliorating short-circuiting growth-enhancing aspect increased secretion.